KYNMOBI (apomorphine HCl) sublingual film
 

KYNMOBI™ (apomorphine hydrochloride) sublingual film is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).

INDICATION AND IMPORTANT SAFETY INFORMATION FOR KYNMOBI

IMPORTANT SAFETY INFORMATION for KYNMOBI (apomorphine hydrochloride) Sublingual Film

Contraindications: KYNMOBI is contraindicated in patients:

Warnings and Precautions:

Most Common Adverse Reactions: Most common adverse reactions (incidence at least 10% in patients treated with KYNMOBI and with an incidence greater than placebo) were nausea, oral/pharyngeal soft tissue swelling, oral/pharyngeal soft tissue pain and paraesthesia, dizziness, and somnolence. 


INDICATION

KYNMOBI (apomorphine hydrochloride) sublingual film is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Instructions for Use for KYNMOBI at www.kynmobi.com.


Reference:
KYNMOBI (apomorphine hydrochloride) [Prescribing Information]. Sunovion Pharmaceuticals Inc., Marlborough, MA. May 2020.